Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...
FRANKFURT (Reuters) - Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a ...
With a growing portfolio in an attractive rare-disease niche—and acceleration of profit growth beginning in 2022—BioMarin could be an acquisition target for pharmaceutical firms with pipelines to fill ...